Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Luis Ostrosky, ACR 2021: Therapeutic Options for COVID-19

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 12th 2021

TouchIMMUNOLOGY were delighted to talk with Professor Luis Ostrosky (Infectious diseases, UTHealth, Houston, TX, USA) around his presentation titled ‘COVID-19: Update on Therapeutics‘, which was presented at the ACR Convergence, 3-9 November 2021.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

Questions

  1. What are the challenges presented by interpreting clinical study data of potential therapeutic options for COVID-19? (0:26)
  2. What are the latest recommendations on neutralising monoclonal antibodies and IL-6 blockers? (1:15)
  3. What novel strategies seem promising for the treatment of patients with COVID-19? (3:10)

Disclosures: Dr. Ostrosky has received research funding and/or personal fees from Abbott, Gilead, Octpharma, Pfizer, and GigaGen.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the virtual ACR Convergence 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup